Last reviewed · How we verify
Imodium Multi-Symptom Relief (DIMETHICONE)
At a glance
| Generic name | DIMETHICONE |
|---|---|
| Sponsor | Mcneil |
| Drug class | dimethicone |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Diaper rash
Common side effects
Key clinical trials
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- Metronidazole SC Penetrance With Moisturizers (NA)
- Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa. (PHASE2)
- The Study on the Effect of Different Administration Methods of Simethicone in Reducing Bubbles During Bowel Preparation (PHASE4)
- Effect of Premedication With Pronase on Mucosal Cleanliness During EGD (NA)
- Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand (PHASE4)
- Comparative Head Lice Therapy With Dimet 5® vs. Hedrin® Once
- A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imodium Multi-Symptom Relief CI brief — competitive landscape report
- Imodium Multi-Symptom Relief updates RSS · CI watch RSS
- Mcneil portfolio CI